Patient-specific prescription compounding
Wells identifies its Ocala facility as a 503A pharmacy for patient-specific prescriptions.
Provider source ↗
Identity checked8 services cataloged
Wells Pharmacy Network and Wells Pharma of Houston
Ocala, FL · In-person care
Provider overview
About Wells Pharmacy Network and Wells Pharma of Houston
Wells Pharmacy Network publishes a closed-door 503A pharmacy in Ocala and a Wells Pharmacy, Inc. 503B outsourcing facility in Dyersburg; FDA's current table also lists the affiliated Wells Pharma of Houston facility. The current FDA table shows both 503B entries registered and shows open regulatory actions associated with their latest 2026 inspections. Registration is not FDA approval of a facility or its compounded drugs and does not establish ongoing compliance, safety, or effectiveness. Because the official site says only 'most states' without a current state table, structured coverage is limited to Florida, Tennessee, and Texas facility states.
At a glance
- Market role
- 503A compounding pharmacy · 503B outsourcing facility
- Care model
- Not published
- Coverage
- 3 listed jurisdictions
- Pharmacy pathway
- 503A and 503B publicly supported
503A and 503B labels describe statutory compounding pathways or public relationships. They do not mean a compounded drug is FDA-approved or that FDA endorses a facility.
Service catalog
Programs and services
Provider-advertised services, grouped for quick scanning with all details visible.
01
1503A pharmacy capabilities
02
1503B facility capabilities
Outsourcing-facility compounding
Wells publishes a Dyersburg outsourcing operation; FDA separately lists current Dyersburg and Houston 503B registrations.
Provider source ↗03
2Peptide-related compounding
Sermorelin preparations
The public shop lists sermorelin injection and mini-tablet preparations, subject to prescription and current availability requirements.
Provider source ↗PT-141 nasal preparation
PT-141 nasal preparation appears in the public catalog; inclusion is not an approval or effectiveness claim.
Provider source ↗04
1Longevity and cellular support
NAD+ and GHK-Cu preparations
NAD+ and topical GHK-Cu preparations are listed in the public catalog with ordering subject to the appropriate channel.
Provider source ↗05
1Hormone health
Hormone-replacement compounding
Bioidentical hormone and other hormone-related compounding are included in the pharmacy's published practice areas.
Provider source ↗06
1Metabolic health
Weight-management compounding
Wells publishes weight-management compounding among its practitioner-focused service areas.
Provider source ↗07
1Additional compounding
IV, dermatology, and sexual-health compounding
The organization lists infusion, dermatology, and sexual-health preparations among its compounding categories.
Provider source ↗Important: Inclusion does not establish availability for every patient or state, regulatory status, clinical appropriateness, safety, or effectiveness.
Coverage and research
Explore this provider’s markets
Review every state page this provider advertises serving, then use the related guides to evaluate services and claims.
Continue comparing
Related provider profiles
Evidence
Sources reviewed
Logo reproduced from the provider’s official website for identification. Logo source ↗
These links support the public facts recorded here. Provider-published information is not an independent endorsement.
- 1Wells Pharmacy Network — About ↗
Supports: identity facilities and 503a 503b business lines · Checked Aug 4, 2026
- 2Wells Pharmacy Network — Contact ↗
Supports: phone and locations · Checked Aug 4, 2026
- 3Wells Pharmacy Network — Shop ↗
Supports: specific product catalog · Checked Aug 4, 2026
- 4FDA — Registered Outsourcing Facilities ↗
Supports: 503b registration inspection and regulatory status · Checked Aug 4, 2026